



(11) **EP 2 935 275 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Claims EN 14

(51) Int Cl.:

C07D 487/06 ^(2006.01) **A61K 31/5517** ^(2006.01)

(86) International application number:

PCT/EP2013/076850

(48) Corrigendum issued on:

11.10.2017 Bulletin 2017/41

(87) International publication number:

WO 2014/095822 (26.06.2014 Gazette 2014/26)

(45) Date of publication and mention
of the grant of the patent:

08.03.2017 Bulletin 2017/10

(21) Application number: **13818716.6**

(22) Date of filing: **17.12.2013**

(54) **AN IMPROVED PROCESS FOR MAKING ZILPATEROL**

VERBESSERTE HERSTELLUNGSVERFAHREN VON ZILPATEROL

PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DU ZILPATEROL

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(72) Inventors:

- **TOWSON, James C.**
Summit, New Jersey 07901 (US)
- **WONG, Shing-Chun**
Summit, New Jersey 07901 (US)

(30) Priority: **18.12.2012 US 201261738438 P**

(43) Date of publication of application:

28.10.2015 Bulletin 2015/44

(74) Representative: **Intervet International B.V.**

Hertford Road
Hoddesdon, Hertfordshire EN11 9BU (GB)

(73) Proprietor: **Intervet International B.V.**

5831 AN Boxmeer (NL)

(56) References cited:

WO-A1-2008/044127 WO-A1-2008/050207
WO-A1-2008/119754

EP 2 935 275 B9


Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

BACKGROUND


[0001] Zilpaterol is a β -adrenergic agonist used as a feed additive for cattle at slaughter age that has been shown to increase their average daily gain. U.S. Patent No. 4,900,735 describes zootechnical compositions of racemic *trans* zilpaterol and its derivatives can be used to increase the rate of weight gain, improve the feed efficiency and increase carcass leanness in livestock, poultry and fish.

[0002] Methods for making zilpaterol are known in the art. For example, in U.S. Patent No. 4,585,770, Fréchet et al. discuss compounds encompassed by a genus characterized as 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2(1H)-one derivatives and pharmaceutically acceptable acid addition salts thereof. The derivatives correspond in structure to the following formula:




[0003] Here, R can be various substituents, and the wavy lines indicate that the bonds to the 6-amino and 7-OH groups have the *trans* configuration. This genus encompasses racemic *trans* zilpaterol when R is isopropyl.

[0004] The methods reported in U.S. No. Patent 4,585,770 use 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7(1H)-trione-6-oxime as an intermediate. This compound corresponds to the following structure:




[0005] As indicated in U.S. Patent No. 4,585,770, 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7(1H)-trione-6-oxime may be formed from starting materials that have been long known in the art. U.S. Patent No. 4,585,770 illustrates the use of two such starting materials. In both examples, the starting materials are used to form 5,6-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,7-(1H,4H)-dione, which, in turn, may be used to make 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7(1H)-trione-6-oxime.

[0006] In one of the examples in U.S. Patent No. 4,585,770, the starting material is 1,3-dihydro-1-(1-methylethenyl)-2H-benzimidazol-2-one, which is described in J. Chem. Soc. Perkins, p. 261 (1982):



1,3-dihydro-1-(1-methylethenyl)-2H-benzimidazol-2-one


[0007] U.S. Patent No. 4,585,770 indicates that 1,3-dihydro-1-(1-methylethenyl)-2H-benzimidazol-2-one may be reacted with an alkyl 4-halobutyrate (*i.e.*, $R^A-(CH_2)_3-COOR^B$ (wherein R^A is Cl, Br, or I; and R^B is C_1 - C_4 -alkyl), such as methyl or ethyl 4-bromobutyrate) and a base (*e.g.*, an alkali metal) to form a butanoate, which, in turn may be hydrolyzed with an acid (*e.g.*, H_2SO_4) in an alkanol (*e.g.*, methanol or ethanol) to remove the methylethenyl substituent. The hydrolysis product then may be subjected to saponification by reacting it with a base (*e.g.*, NaOH or KOH) in an alkanol to form a carboxylic acid. Subsequently, the carboxylic-acid-terminated side chain may be cyclized to form 5,6-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,7-[1H,4H]-dione by reacting the carboxylic acid with thionyl chloride to obtain a chloride, and then treating the chloride with a Lewis acid (*e.g.*, aluminum chloride) in an organic solvent (*e.g.*, methylene chloride or dichloroethane):



[0008] See U.S. Patent No. 4,585,770, col. 4, line 3 to col. 5, line 14; and Example 14, col. 12, lines 1-68.

[0009] In another example in U.S. Patent No. 4,585,770, the starting material is 1,3-dihydro-1-benzyl-2H-benzimidazol-


2-one, which is described in Helv., Vol 44, p. 1278 (1961):



1,3-dihydro-1-benzyl-2H-benzimidazol-2-one

[0010] U.S. Patent No. 4,585,770 indicates that the 1,3-dihydro-1-benzyl-2H-benzimidazol-2-one may be reacted with ethyl 4-bromobutyrate and sodium hydride to form 1,3-dihydro-2-oxo-3-benzyl-1H-benzimidazol-1-butanoate, which, in turn may be subjected to saponification by reacting it with methanolic NaOH to form 1,3-dihydro-2-oxo-3-benzyl-1H-benzimidazol-1-butanoic acid. The butanoic acid side chain may then be cyclized by reacting the 1,3-dihydro-2-oxo-3-benzyl-1H-benzimidazol-1-butanoic acid with thionyl chloride to obtain a chloride, and then treating the chloride with aluminum chloride in dichloroethane. The cyclized product, in turn, may be hydrolyzed using o-phosphoric acid in phenol to form 5,6-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,7-[1H,4H]-dione. See US Patent 4,585,770, Example 1, Steps A-D, col. 6, line 10 to col. 7, line 35.


[0011] Using the methods reported in U.S. Patent No. 4,585,770, 5,6-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,7-[1H,4H]-dione may be reacted with an alkyl nitrite (e.g., tert-butyl nitrite or isoamyl nitrite), in the presence of a base or acid (e.g., HCl), to form 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7[1H]-trione-6-oxime. The 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7[1H]-trione-6-oxime, in turn, is reduced via catalytic hydrogenation (with, for example, hydrogen in the presence of palladium on carbon) and/or sodium borohydride to form racemic *trans* 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2[1H]-one:



[0012] In the illustrative example in U.S. Patent No. 4,585,770, the 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7[1H]-trione-6-oxime is converted into racemic *trans* 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2[1H]-one in two steps: the 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7[1H]-trione-6-oxime is first reacted with H₂ in the presence of Pd on carbon, and, then, after filtration, the hydrogenation product is reacted with sodium borohydride. See U.S. Patent No. 4,585,770, col. 2, line 50 to col. 4, line 2; and Example 1, Steps E & F, col. 7, line 38


to col. 8, line 3.

[0013] U.S. Patent No. 4,585,770 reports that the *trans* stereoisomers of 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2(1H)-one may be alkylated with acetone in the presence of a reducing agent (e.g., an alkali metal borohydride or cyanoborohydride, such as sodium cyanoborohydride) to form racemic *trans* zilpaterol:



In U.S. Patent Nos. 5,731,028 and 5,847,124, Chevremont et al. discuss crystallized anhydrous zilpaterol hydrochloride, and particularly crystallized anhydrous zilpaterol hydrochloride wherein less than 5% of the crystals have a size of less than 15 μm , and at least 95% of the crystals have a size of less than 250 μm . According to Chevremont et al., such crystals may be incorporated into animal feed to increase body weight and meat quality. Chevremont et al. provide methods for making such crystals, and discuss using the crystals to make animal premixes in which the crystals are secured to a corn cob support having a greater particle size. They also discuss monohydrate and trihydrate intermediates that can be useful in, for example, making the crystals.

[0014] WO 2008/119754 discloses a process to make zilpaterol as shown in Scheme 1 below



Scheme 1. Current Synthetic Route to (+/-)-Zilpaterol

[0015] In addition to the above process, WO 2008/119754 also discloses methods of preparing zilpaterol hydrochloride from zilpaterol freebase. WO2010/070004 describes further processes for making crystalline zilpaterol salts, particularly zilpaterol hydrochloride.


[0016] WO 2008/006828 discloses zilpaterol enantiomer compositions and methods of making and using such compositions to increase rate of weight gain, improve feed efficiency and increase carcass leanness in livestock, poultry and fish. In WO 2008/092924, the enantioselective synthesis of zilpaterol and intermediates is disclosed.

[0017] WO 2008/044127 discloses non zilpaterol beta-2-adrenoreceptor agonists and methods of their preparation.

[0018] Alternative process intermediates have been envisioned herein that could shorten the zilpaterol production process and lower manufacturing cost.


SUMMARY OF THE INVENTION

[0019] An embodiment of the invention is a method of preparing a compound of Formula I or a salt thereof




15 comprising:

a. reacting a compound of Formula II



30 with a halogenating agent to produce a compound of Formula III




40 wherein X is Cl, Br, or I;

b. reacting compound III with a compound of Formula A



55 to produce a compound of Formula IV;



IV

and

c. reacting compound IV with a reducing agent to produce a compound of Formula I wherein:

R₁ is selected from hydrogen, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, and any cyclic version or heteroatom containing version may be substituted or unsubstituted;

R_{2a} and R_{2b} are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio and any cyclic version or heteroatom containing version may be substituted or unsubstituted;

R₃ is selected from hydrogen, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio and any cyclic version or heteroatom containing version may be substituted or unsubstituted; and

R₄ and R₅ are independently selected from hydrogen, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, and any cyclic version or heteroatom containing version may be substituted or unsubstituted.

[0020] In another embodiment, R₄ and R₅ may be taken together to form a cyclic substituent. This cyclic substituent may be aromatic or non aromatic and may further include one or more additional hetero atoms selected from O, S and N.


[0021] In another embodiment, the reducing agent is NaBH₄

[0022] In another embodiment, R₁ - R₃ and R₅ are hydrogen. In another embodiment, R₄ is isopropyl.


[0023] In another embodiment, the zilpaterol is zilpaterol hydrochloride.

DETAILED DESCRIPTION

[0024] The present invention relates to certain process improvements that are envisioned over current preparations of zilpaterol. Process improvement would help to satisfy the production of larger quantities of zilpaterol at a reduced price. The present invention also relates to process for making zilpaterol analogs of Formula (I) wherein R₁-R₅ are defined below. Finally, the present invention relates to novel compounds which are intermediates in the process.




(+/-)-Zilpaterol



I


[0025] Scheme 2 provides a summary of the improved process. Specifically, beginning with ketone **3**, alternative routes have been employed to expedite the synthesis of (+/-)-zilpaterol.



Scheme 2. Synthesis of (+/-)-zilpaterol from Ketone **3**


Beginning with the synthesized Compound **3**, from Scheme 1, an α -halogenation using, for example, N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), bromine or iodine is employed to provide Intermediate **9** wherein X = Cl, Br or I. The α -halogenation of ketones with NCS, NBS, and NIS is a well-known and efficient reaction in organic chemistry. However, this reaction has never been documented with the (+/-)-zilpaterol process, and it offers significant improvement relative to the current manufacturing method. Towards this end, the chemistry leading to the bromide version of this molecule (**9**, X = Br) has been reduced to practice in 65 % yield. A nucleophilic substitution of the halide from **9** using, for example, inexpensive isopropylamine afforded Compound **10**. A hydride reduction of the ketone in **10** completed the new process and delivered (+/-)-zilpaterol (**8**). Possible reducing agents for this final step can include but are not limited to sodium borohydride, potassium borohydride, lithium aluminum hydride and borane-tetrahydrofuran complex. The displacement followed by reduction of the α -aminoketone, **10**, gave a ^1H NMR spectrum that contained a very distinct signal near 4 ppm, which is characteristic of (+/-)-zilpaterol. In an embodiment, the reactions from compound **9** to compound **10** and from compound **10** to compound **8** are conducted in situ. Compound **10** can be but does not need to be isolated.

[0026] An embodiment of the invention is a method of preparing a compound of Formula I or a salt thereof




comprising:

- a. reacting a compound of Formula II



with a halogenating agent to produce a compound of Formula III




wherein X is Cl, Br, or I;

b. reacting compound III with a compound of Formula A



to produce a compound of Formula IV;



and

c. reacting compound IV with a reducing agent to produce a compound of Formula I wherein:

R_1 is selected from hydrogen, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, and any cyclic version or heteroatom containing version may be substituted or unsubstituted;

R_{2a} and R_{2b} are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio and any cyclic version or heteroatom containing version may be substituted or unsubstituted;

R_3 is selected from hydrogen, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio and any cyclic version or heteroatom containing version may be substituted or unsubstituted; and

R_4 and R_5 are independently selected from hydrogen, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, and any cyclic version or heteroatom containing version may be substituted or unsubstituted.

[0027] In another embodiment, R_4 and R_5 may be taken together to form a cyclic substituent. This cyclic substituent

may be aromatic or non aromatic and may further include one or more additional hetero atoms selected from O, S and N.

[0028] In an alternative embodiment, R_1 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} alkynyl, or any cyclic version or heteroatom containing version thereof and wherein for each C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} alkynyl, and any cyclic version or heteroatom containing version may be substituted or unsubstituted;

[0029] In an alternative embodiment, R_{2a} and R_{2b} are each independently selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} alkynyl, C_{1-10} alkoxy, C_{1-10} alkylthio, C_{1-10} alkyl sulfonyl, C_{1-10} alkyl sulfoxy, C_{1-10} alkyl thio or any cyclic version or heteroatom containing version thereof and wherein for each C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} alkynyl, C_{1-10} alkoxy, C_{1-10} alkylthio, C_{1-10} alkyl sulfonyl, C_{1-10} alkyl sulfoxy, C_{1-10} alkyl thio and any cyclic version or heteroatom containing version may be substituted or unsubstituted;

[0030] In an alternative embodiment, R_3 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} alkynyl, C_{1-10} alkoxy, C_{1-10} alkylthio, C_{1-10} alkyl sulfonyl, C_{1-10} alkyl sulfoxy, C_{1-10} alkyl thio or any cyclic version or heteroatom containing version thereof and wherein for each C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} alkynyl, C_{1-10} alkoxy, C_{1-10} alkylthio, C_{1-10} alkyl sulfonyl, C_{1-10} alkyl sulfoxy, C_{1-10} alkyl thio and any cyclic version or heteroatom containing version may be substituted or unsubstituted; and

[0031] In an alternative embodiment, R_4 and R_5 are independently selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} alkynyl, or any cyclic version or heteroatom containing version thereof and wherein for each C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} alkynyl, and any cyclic version or heteroatom containing version may be substituted or unsubstituted.

[0032] In an embodiment, the reactions from compound III to compound IV and from compound IV to compound I are conducted in situ. Compound IV is not isolated.

[0033] In an embodiment, the halogenating agent is selected from N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), bromine and iodine.

[0034] In an embodiment, the reducing agent is selected from sodium borohydride, potassium borohydride, lithium aluminum hydride and borane-tetrahydrofuran complex.

[0035] In another embodiment, the reducing agent is $NaBH_4$.


[0036] In another embodiment, $R_1 - R_3$ and R_5 are hydrogen. In another embodiment, R_4 is isopropyl.

[0037] In another embodiment, the zilpaterol is zilpaterol hydrochloride.

[0038] Alternative suitable salts generally include acid addition salts. In general, an acid addition salt can be prepared by reacting the zilpaterol free base with an approximately stoichiometric amount of an inorganic or organic acid. Examples of often suitable inorganic acids for making pharmaceutically acceptable salts include hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid. Examples of often suitable organic acids for making pharmaceutically acceptable salts generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids. Specific examples of often suitable organic acids include cholate, sorbate, laurate, acetate, trifluoroacetate (or " CF_3COOH " or "TFA"), formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, aryl carboxylic acid (e.g., benzoate), anthranilic acid, mesylate, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), alkylsulfonate (e.g., ethanesulfonate), arylsulfonate (e.g., benzenesulfonate), pantothenate, 2-hydroxyethanesulfonate, sulfanilate, cyclohexylaminosulfonate, β -hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, heptanoate, hexanoate, nicotinate, 2-naphthalesulfonate, oxalate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, thiocyanate, tosylate, and undecanoate. In some such embodiments, for example, the salt comprises a trifluoroacetate, mesylate, or tosylate salt.


[0039] In one embodiment, the invention is a method of preparing zilpaterol comprising:

a. reacting a compound of Formula 3




3

with a halogenating agent to produce a compound of Formula 9


**9**

wherein X is Cl, Br, or I;

b. reacting compound 9 with a compound of Formula A

**A**

to produce a compound of Formula 10;

**10**

and


c. reacting compound 10 with reducing agent to produce zilpaterol.

[0040] In another embodiment, the halogenating agent is selected from N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), bromine and iodine.

[0041] In another embodiment, the reducing agent is selected from sodium borohydride, potassium borohydride, lithium aluminum hydride and borane-tetrahydrofuran complex.

[0042] In another embodiment, the reducing agent is NaBH_4


[0043] In another embodiment, this route may be used to produce zilpaterol analogs. See Formula (Ia) below. This route can be amenable to a variety of R substituents (see Formula (II)), thereby permitting the preparation of derivatives of zilpaterol. In an alternative embodiment, R_1 may be affixed throughout any stage of the synthesis. In yet another embodiment, the R_2 s may be the same or different. In a further embodiment, the R_2 s may be affixed preceding preparation of Compound 1 in Scheme 1. Examples of R_1 , may be selected from among but are not limited to hydrogen, alkyl, alkenyl, alkynyl, aryl, benzyl, and any cyclic version or heteroatom containing version thereof. R_{2a} and R_{2b} and R_3 may be selected from among but are not limited to hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, and any cyclic version or heteroatom containing version thereof. In each R, the alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, and any cyclic version or heteroatom containing version may be substituted or unsubstituted.



II


Analogs of Intermediate 3

Formula (II)




Scheme 3. Synthesis of analogues of zilpaterol (Formula I) from the ketone of Formula II

[0044] Additional embodiments of the method are given in Scheme 4 below.




Scheme 4. Alternative routes where the amino group is initially added unsubstituted and then the substitution is added either prior to or after the reduction of the ketone to an alcohol. R_1 to R_3 are defined as above.

[0045] In an alternative embodiment, a method of preparing a compound of Formula Ia or a salt thereof




comprising:

- a. reacting a compound of Formula II



II

with a halogenating agent to produce a compound of Formula III



III


wherein X is Cl, Br, or I;

b. reacting compound III with a compound of Formula A




A

wherein R₄ and R₅ of Formula A are hydrogen, to produce a compound of Formula VI;




VI

c. reacting the compound of Formula VI with acetone to form the compound of Formula VII




and

d. reacting the compound of Formula VII with a reducing agent to produce a compound of Formula Ia or a salt thereof




[0046] In yet another alternative embodiment, a method of preparing a compound of Formula Ia or a salt thereof




comprising:

a. reacting a compound of Formula II



with a halogenating agent to produce a compound of Formula III




wherein X is Cl, Br, or I;


b. reacting compound III with a compound of Formula A




wherein R₄ and R₅ of Formula A are hydrogen, to produce a compound of Formula VI;



c. reacting the compound of Formula VI with a reducing agent to form the compound of Formula VIII




d. reacting the compound of Formula VIII with acetone to produce a compound of Formula IX



and

e. reacting the compound of Formula IX with a reducing agent to produce a compound of Formula Ia or a salt thereof




[0047] In another embodiment, the compound of Formula Ia is zilpaterol, wherein $R_1 - R_3$ are hydrogen.

[0048] In another embodiment, the halogenating agent is selected from N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), bromine and iodine.

[0049] In another embodiment, the reducing agent is selected from sodium borohydride, potassium borohydride, lithium aluminum hydride and borane-tetrahydrofuran complex.

[0050] Other embodiments of the subject invention are the novel intermediate compounds 9a, 9b, 9c and 10. In compound 9a, X is Br; in compound 9b, X is Cl; and in compound 9c, X is I.



[0051] The inventors disclose herein an improved process for the preparation of (+/-)-zilpaterol (**8**). One advantage of the present invention is that it can shorten the manufacturing process of converting Intermediate **3** into (+/-)-zilpaterol by two processing steps or 40% fewer steps. Another advantage of the present invention is that it utilizes inexpensive and commercially available reagents. Yet another advantage of the present invention is that it does not require the use of the expensive catalytic reducing agents of the current manufacturing process. Still yet another advantage of the present invention over previous procedures is that it allows for modification of compound **3** which could produce various analogues of zilpaterol. Moreover, another object of the present invention is that it precedes through previously unknown intermediates **9** and **10**, for which composition of matter is claimed. Combined these features may afford a scaleable and economical process suitable for large-scale production of (+/-)-zilpaterol (**8**) at reduced cost.

[0052] In another embodiment, it is envisioned the disclosed processes could be used to prepare other non zilpaterol beta-2-adrenoceptor agonists such as those disclosed in WO 2008/044127.

[0053] The term "alkyl" means a saturated straight or branched alkyl such as methyl, ethyl, propyl, or sec-butyl. Alternatively, the number of carbons in an alkyl can be specified. For example, "C₁₋₁₀ alkyl" means an "alkyl" as described above containing 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms.

[0054] The term "C₂₋₁₀ alkenyl" means an unsaturated branched or unbranched hydrocarbon group having at least one double carbon-carbon (-C=C-) bond and containing 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. Example alkenyl groups include, without limitation, ethenyl, 1-propenyl, isopropenyl, 2-butenyl, 1,3-butadienyl, 3-pentenyl and 2-hexenyl, and the like.

[0055] The term "C₂₋₁₀ alkynyl" means an unsaturated branched or unbranched hydrocarbon group having at least one triple carbon-carbon (-C≡C-) bond and containing 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. Example alkynyl groups include, without limitation, ethynyl, 1-propynyl, 2-propynyl, 2-butyne, 3-butyne, 2-penten-4-ynyl, and the like.

[0056] The term "C₁₋₁₀ alkoxy" means an alkyl-O- group, where the term "alkyl" is defined herein. Example alkoxy groups include, without limitation, methoxy, ethoxy, propoxy (e.g., *n*-propoxy and isopropoxy), *t*-butoxy, and the like.

[0057] The term "aryl" means phenyl, or phenyl substituted by C₁ to C₆ alkyl or "halo", where phenyl and halo are as defined herein.

[0058] The term "bromo" means the chemical element bromine.

[0059] The term "chloro" means the chemical element chlorine.

[0060] The term "NXS" means N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), or N-iodosuccinimide (NIS), where X is Cl, Br or I, respectively.

[0061] Throughout the specification and the appended claims, a given chemical formula or name shall encompass all stereo and optical isomers and racemates thereof, as well as mixtures in different proportions of the separate enantiomers, where such isomers and enantiomers exist, as well as pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates. Isomers can be separated using conventional techniques, e.g. chromatography or fractional crystallization. The enantiomers can be isolated by separation of a racemic mixture, for example, by fractional crystallization, resolution or high-performance (or -pressure) liquid chromatography (HPLC). The diastereomers can be isolated by separation of isomer mixtures, for instance, by fractional crystallization, HPLC or flash chromatography. The stereoisomers also can be made by chiral synthesis from chiral starting materials under conditions which will not cause racemization or epimerization, or by derivatization, with a chiral reagent. The starting materials and conditions will be within the skill of one skilled in the art. All stereoisomers are included within the scope of the invention.

EXAMPLES

Example 1: Preparation of 7-bromo-8,9-dihydro-2,9a-diazabenz[cd]azulene-1,6(2H,7H)-dione (**9a**):


[0062] Ketone (**3**) (10.0 g, 49.4 mmol) was suspended in ethyl acetate (500 mL) and stirred at room temperature. N-Bromosuccinimide (previously recrystallized from hot water) (9.24 g, 51.9 mmol) and Amberlyst-15 (15 g) were then added and the reaction was stirred at 23°C. After 14 h, the reaction was filtered and the solid was washed with ethyl acetate (2 X 100 mL). The filtrate was discarded and the solid material added to hot methanol (~500 mL). The remaining Amberlyst-15 was removed from the methanol solution via filtration, and the methanol was removed by rotary evaporator to furnish 8.98 g of **9a** (31.9 mmol, 65% yield) of a beige solid. ¹H NMR (DMSO-d₆, 250 MHz): δ 2.48-2.65 (m, 2H), 3.89-3.99 (m, 1H), 4.18-4.27 (m, 1H), 5.30 (dd, J = 2.5 Hz, 12 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 7.24 (d, J = 7.4 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H), 11.4 (br s, 1H); HRMS (ESI): calcd for C₁₁H₉BrN₂O₂ [M+Na] = 302.97, found 302.9721.

Example 2: Preparation of 7-chloro-8,9-dihydro-2,9a-diazabenz[cd]azulene-1,6(2H,7H)-dione (**9b**):

[0063] The chloro ketone was prepared by the method described to prepare **9a** using 1.00 g (4.94 mmol) of ketone **3**, N-chlorosuccinimide (990 mg, 7.41 mmol), Amberlyst-15 (1.5 g), and 50 mL of ethyl acetate. The chloro ketone product **9b** was isolated in 72% yield (842.5 mg, 3.56 mmol) as a light yellow solid. ¹H NMR (DMSO-d₆, 250 MHz): δ 2.51-2.71 (m, 2H), 3.84-3.98 (m, 1H), 3.99-4.09 (m, 1H), 5.28 (dd, J = 2.5 Hz, 7.5 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 7.24 (d, J = 7.4 Hz, 1H), 7.58 (d, J = 7.5 Hz, 1H), 11.4 (br s, 1H).

Example 3: 7-iodo-8,9-dihydro-2,9a-diazabenz[cd]azulene-1,6(2H,7H)-dione (**9c**):

[0064]



[0065] Procedure: Into a 4 mL vial equipped with a stir bar was added buzolinone (0.101 g; 0.50 mmol), iodine (0.63 g; 2.5 mmol; 5 equiv), and 1,2-dimethoxyethane (2.5 mL). The vial is capped and the deep red solution is stirred for 12 h at 105 °C. The reaction mixture is diluted with CH₂Cl₂ (50 mL) and washed with sat. Na₂S₂O_{3(aq)} (50 mL). The aqueous layer is separated and extracted with CH₂Cl₂ (2 x 50 mL). The combined organic layers are dried over Na₂SO₄, filtered, and concentrated to yield C₁₁H₉IN₂O₂ (0.153 g; 94%) as a yellow solid. ¹H NMR (DMSO-d₆, 400 MHz): δ 2.15-2.21 (m, 1H), 2.33-2.40 (m, 1H), 3.84-3.91 (m, 1H), 4.32-4.37 (m, 1H), 5.42-5.43 (m, 1H), 7.08 (m, 1H), 7.23 (dd, J = 7.5, 1.0 Hz, 1H), 7.57 (dd, J = 8.2, 1.0 Hz), 11.4 (br s, 1H); HRMS (ESI): calcd for C₁₁H₉IN₂O₂ [M+Na] = 350.9601, found 350.9588.


Example 4: Preparation of (6*R*,7*R*)-*rel*-4,5,6,7-tetrahydro-7-hydroxy-6-[(1-methylethyl)amino]-imidazo[4,5,1-*jk*][1]benzazepin-2(1*H*)-one (**8**) through (**10**):

[0066] To a small vial equipped with a stir bar was added bromoketone (**9a**) (141 mg, 0.500 mmol). The vial was capped with a septum and backfilled with argon three times. Dry, distilled dimethylformamide (DMF) (1.0 mL) was added to the flask and the reaction mixture was stirred. Isopropylamine (0.46 mL, 5.00 mmol) was added and the reaction was stirred at 23 °C for 15 min. After this time, sodium borohydride (38 mg, 1.0 mmol) was added and the reaction was stirred for 15 min. The vial was transferred to a 50-mL round-bottom flask, and the flask was placed under high vacuum. Upon removal of all volatile components, the remaining crude residue was dissolved in 10% methanol/dichloromethane (MeOH/DCM), and silica gel was added. The solvent was then removed and the silica gel containing the product was loaded onto a silica gel column and purified using 20% MeOH/DCM with 1% NEt₃ (*R_f* = 0.2). The free base zilpaterol (**8**) was isolated in 52% yield (68 mg, 0.26 mmol) as a white solid. ¹H NMR (CD₃OD, 400 MHz): 1.38 (d, *J* = 6.4 Hz, 3H), 1.43 (d, *J* = 6.4 Hz, 3H), 2.09–2.13 (m, 1H), 2.51–2.68 (m, 1H), 3.60–3.63 (m, 2H), 3.89–3.96 (m, 1H), 4.4.23–4.28 (m, 1H), 4.97 (d, *J* = 8.4 Hz, 1H), 7.08–7.16 (m, 2H), 7.33 (d, *J* = 7.6 Hz, 1H); HRMS (ESI): calcd for C₁₄H₁₉N₃O₂ [*M*+]⁺ = 261.15, found 261.9500.

[0067] The words "process" and "method" are used interchangeably in this patent. All references cited in this patent are incorporated by reference into this patent. The above detailed description of preferred embodiments is intended only to acquaint others skilled in the art with the invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This invention, therefore, is not limited to the above embodiments, and may be variously modified.


Claims

1. A method of preparing a compound of Formula I or a salt thereof




comprising:

a. reacting a compound of Formula II



with a halogenating agent to produce a compound of Formula III




wherein X is Cl, Br, or I;

b. reacting compound III with a compound of Formula A



to produce a compound of Formula IV;



and

c. reacting compound IV with a reducing agent to produce a compound of Formula I wherein:

R_1 is selected from hydrogen, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, and any cyclic version or heteroatom containing version may be substituted or unsubstituted;

R_{2a} and R_{2b} are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio and any cyclic version or heteroatom containing version may be substituted or unsubstituted;

R_3 is selected from hydrogen, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio and any cyclic version or heteroatom containing version may be substituted or unsubstituted; and R_4 and R_5 are independently selected from hydrogen, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, and any cyclic version or heteroatom containing version may be substituted or unsubstituted; or R_4 and R_5 may be taken together to form a cyclic substituent, wherein the cyclic substituent may be aromatic or non aromatic and may further include one or more additional hetero atoms selected from O, S and N.

2. The method of claim 1, wherein the reaction of part b and the reaction of part c are conducted in situ and compound

IV is not isolated.

3. The method of claim 1, wherein $R_1 - R_3$ and R_5 are hydrogen


4. The method of claim 1, wherein R_4 is isopropyl.

5. The method of any one of claims 1-4 wherein the reducing agent is selected from sodium borohydride, potassium borohydride, lithium aluminum hydride and borane-tetrahydrofuran complex preferably NaBH_4 .

6. The method of any one of claims 1-5, wherein the halogenating agent is selected from N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), bromine and iodine, preferably NBS.


7. A method of preparing zilpaterol or a salt thereof comprising:

a. reacting a compound of Formula 3



3


with a halogenating agent to produce a compound of Formula 9




9

wherein X is Cl, Br, or I;

b. reacting compound 9 with the following compound




to produce a compound of Formula 10;



and

c. reacting compound 10 with a reducing agent to produce zilpaterol or a salt thereof.

8. The method of claim 7, wherein the reaction of part b and the reaction of part c are conducted in situ and compound 10 is not isolated.
9. The method of claim 7, wherein the zilpaterol is zilpaterol hydrochloride.
10. The method of any one of claims 7 to 9, wherein the halogenating agent is selected from N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), bromine and iodine.
11. The method of any one of claims 7 to 10 wherein the reducing agent is selected from sodium borohydride, potassium borohydride, lithium aluminum hydride and borane-tetrahydrofuran complex.
12. The compound of Formula III or salt thereof



wherein


X is Cl, Br, or I;

R₁ is selected from hydrogen, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, and any cyclic version or heteroatom containing version may be substituted or unsubstituted;

R_{2a} and R_{2b} are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio and any cyclic version or heteroatom containing version may be substituted or unsubstituted; and

R₃ is selected from hydrogen, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio or any cyclic version or heteroatom containing version thereof and wherein for each alkyl, alkenyl, alkynyl, aryl, benzyl, alkoxy, alkylthioxy, alkyl sulfonyl, alkyl sulfoxy, alkyl thio and any cyclic version or heteroatom containing version may be substituted or unsubstituted.

13. The compound of claim 12 or salt thereof, wherein the compound is of Formula 9




9

;


wherein X is Br, Cl or I preferably Br.

14. The compound of Formula IV or salt thereof



IV


wherein the compounds is of formula 10



10

Patentansprüche


1. Verfahren zum Herstellen einer Verbindung der Formel I oder eines Salzes davon



I


umfassend:

a. Umsetzen einer Verbindung der Formel II



II

mit einem Halogenierungsmittel, um eine Verbindung der Formel III zu erhalten,



III


wobei X Cl, Br oder I ist;

b. Umsetzen von Verbindung III mit einer Verbindung der Formel A,



A

um eine Verbindung der Formel IV zu erhalten;



IV

und

c. Umsetzen von Verbindung IV mit einem Reduktionsmittel, um eine Verbindung der Formel I zu erhalten, wobei:

R_1 ausgewählt ist aus Wasserstoff, Amino, Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl und jeder cyclischen Version oder Heteroatom-enhaltenden Version davon, und wobei jedes Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl und jede cyclische Version oder Heteroatom-enhaltende Version substituiert oder unsubstituiert sein kann;
 R_{2a} und R_{2b} gleich oder verschieden sind und jeweils unabhängig ausgewählt sind aus Wasserstoff, Ha-

logen, Hydroxy, Amino, Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl, Alkoxy, Alkylthioxy, Alkylsulfonyl, Alkylsulfoxy, Alkylthio und jeder cyclischen Version oder Heteroatom-enthaltenden Version davon, und wobei jedes Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl, Alkoxy, Alkylthioxy, Alkylsulfonyl, Alkylsulfoxy, Alkylthio und jede cyclische Version oder Heteroatom-enthaltende Version substituiert oder unsubstituiert sein kann;

R₃ ausgewählt ist aus Wasserstoff, Halogen, Hydroxy, Amino, Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl, Alkoxy, Alkylthioxy, Alkylsulfonyl, Alkylsulfoxy, Alkylthio und jeder cyclischen Version oder Heteroatom-enthaltenden Version davon, und wobei jedes Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl, Alkoxy, Alkylthioxy, Alkylsulfonyl, Alkylsulfoxy, Alkylthio und jede cyclische Version oder Heteroatom-enthaltende Version substituiert oder unsubstituiert sein kann; und

R₄ und R₅ unabhängig ausgewählt sind aus Wasserstoff, Amino, Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl und jeder cyclischen Version oder Heteroatom-enthaltenden Version davon, und wobei jedes Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl und jede cyclische Version oder Heteroatom-enthaltende Version substituiert oder unsubstituiert sein kann; oder R₄ und R₅ zusammengekommen sein können, um einen cyclischen Substituenten zu bilden, wobei der cyclische Substituent aromatisch oder nichtaromatisch sein kann und ferner ein oder mehrere zusätzliche Heteroatome ausgewählt aus O, S und N enthalten kann.

2. Verfahren gemäß Anspruch 1, wobei die Reaktion von Teil b und die Reaktion von Teil c *in situ* durchgeführt werden und Verbindung IV nicht isoliert wird.

3. Verfahren gemäß Anspruch 1, wobei R₁-R₃ und R₅ Wasserstoff sind.


4. Verfahren gemäß Anspruch 1, wobei R₄ Isopropyl ist.

5. Verfahren gemäß einem der Ansprüche 1-4, wobei das Reduktionsmittel ausgewählt ist aus Natriumborhydrid, Kaliumborhydrid, Lithiumaluminiumhydrid und Boran-Tetrahydrofuran-Komplex, vorzugsweise NaBH₄.

6. Verfahren gemäß einem der Ansprüche 1-5, wobei das Halogenierungsmittel ausgewählt ist aus N-Chlorsuccinimid (NCS), N-Bromsuccinimid (NBS), N-Iodsuccinimid (NIS), Brom und Iod, vorzugsweise NBS.


7. Verfahren zum Herstellen von Zilpaterol oder einem Salz davon, umfassend:

a. Umsetzen einer Verbindung der Formel 3



3


mit einem Halogenierungsmittel, um eine Verbindung der Formel 9 zu erhalten,




9

wobei X Cl, Br oder I ist;

b. Umsetzen von Verbindung 9 mit der folgenden Verbindung,



um eine Verbindung der Formel 10 zu erhalten;



und

c. Umsetzen von Verbindung 10 mit einem Reduktionsmittel, um Zilpaterol oder ein Salz davon zu erhalten.


8. Verfahren gemäß Anspruch 7, wobei die Reaktion von Teil b und die Reaktion von Teil c *in situ* durchgeführt werden und Verbindung 10 nicht isoliert wird.

9. Verfahren gemäß Anspruch 7, wobei das Zilpaterol Zilpaterolhydrochlorid ist.

10. Verfahren gemäß einem der Ansprüche 7 bis 9, wobei das Halogenierungsmittel ausgewählt ist aus N-Chlorsuccinimid (NCS), N-Bromsuccinimid (NBS), N-Iodsuccinimid (NIS), Brom und Iod.

11. Verfahren gemäß einem der Ansprüche 7 bis 10, wobei das Reduktionsmittel ausgewählt ist aus Natriumborhydrid, Kaliumborhydrid, Lithiumaluminiumhydrid und Boran-Tetrahydrofuran-Komplex.

12. Verbindung der Formel III oder Salz davon,



wobei


X Cl, Br oder I ist;

R₁ ausgewählt ist aus Wasserstoff, Amino, Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl und jeder cyclischen Version oder Heteroatom-enthaltenden Version davon, und wobei jedes Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl und jede cyclische Version oder Heteroatom-enthaltende Version substituiert oder unsubstituiert sein kann;

R_{2a} und R_{2b} gleich oder verschieden sind und jeweils unabhängig ausgewählt sind aus Wasserstoff, Halogen, Hydroxy, Amino, Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl, Alkoxy, Alkylthioxy, Alkylsulfonyl, Alkylsulfoxy, Alkylthio und jeder cyclischen Version oder Heteroatom-enthaltenden Version davon, und wobei jedes Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl, Alkoxy, Alkylthioxy, Alkylsulfonyl, Alkylsulfoxy, Alkylthio und jede cyclische Version oder Heteroatom-enthaltende Version substituiert oder unsubstituiert sein kann;

R₃ ausgewählt ist aus Wasserstoff, Halogen, Hydroxy, Amino, Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl, Alkoxy, Alkylthioxy, Alkylsulfonyl, Alkylsulfoxy, Alkylthio und jeder cyclischen Version oder Heteroatom-enthaltenden Version davon, und wobei jedes Alkyl, Alkenyl, Alkynyl, Aryl, Benzyl, Alkoxy, Alkylthioxy, Alkylsulfonyl, Alkylsulfoxy, Alkylthio und jede cyclische Version oder Heteroatom-enthaltende Version substituiert oder unsubstituiert sein kann.

13. Verbindung gemäß Anspruch 12 oder Salz davon, wobei die Verbindung von der Formel 9 ist,




9

;


wobei X Br, Cl oder I ist, vorzugsweise Br.

14. Verbindung der Formel IV oder Salz davon,



IV

wobei die Verbindung von der Formel 10 ist




10

.

Revendications


1. Procédé de préparation d'un composé de formule I ou un sel de celui-ci



I


comprenant :

a. la réaction d'un composé de formule II



II

avec un agent d'halogénéation pour produire un composé de formule III



III


dans laquelle X est Cl, Br, ou I ;

b. la réaction du composé III avec un composé de formule A



A

pour produire un composé de formule IV ;



IV

et

c. la réaction du composé IV avec un agent réducteur pour produire un composé de formule I dans laquelle :

R₁ est choisi parmi hydrogène, amino, alkyle, alcényle, alcynyle, aryle, benzyle, ou une version cyclique ou une version contenant un hétéroatome quelconque de ceux-ci et où chaque alkyle, alcényle, alcynyle, aryle, benzyle, et une version cyclique ou une version contenant un hétéroatome quelconque peut être substitué ou non substitué ;

R_{2a} et R_{2b} sont identiques ou différents et sont chacun indépendamment choisis parmi hydrogène, halogène, hydroxyle, amino, alkyle, alcényle, alcynyle, aryle, benzyle, alcoxy, alkylthioxy, alkylsulfonyl, alkylsulfoxy, alkylthio ou une version cyclique ou une version contenant un hétéroatome quelconque de ceux-ci et où chaque alkyle, alcényle, alcynyle, aryle, benzyle, alcoxy, alkylthioxy, alkylsulfonyl, alkylsulfoxy, alkylthio et une version cyclique ou une version contenant un hétéroatome quelconque peut être substitué ou non substitué ;

R₃ est choisi parmi hydrogène, halogène, hydroxyle, amino, alkyle, alcényle, alcynyle, aryle, benzyle, alcoxy, alkylthioxy, alkylsulfonyl, alkylsulfoxy, alkylthio ou une version cyclique ou une version contenant un hétéroatome quelconque de ceux-ci et où chaque alkyle, alcényle, alcynyle, aryle, benzyle, alcoxy, alkylthioxy, alkylsulfonyl, alkylsulfoxy, alkylthio et une version cyclique ou une version contenant un hétéroatome quelconque peut être substitué ou non substitué ; et

R₄ et R₅ sont indépendamment choisis parmi hydrogène, amino, alkyle, alcényle, alcynyle, aryle, benzyle, ou une version cyclique ou une version contenant un hétéroatome quelconque de ceux-ci et où chaque alkyle, alcényle, alcynyle, aryle, benzyle, et une version cyclique ou une version contenant un hétéroatome quelconque peut être substitué ou non substitué ; ou R₄ et R₅ peuvent former conjointement un substituant cyclique, où le substituant cyclique peut être aromatique ou non aromatique et peut comprendre en outre un ou plusieurs hétéroatomes additionnels choisis parmi O, S et N.

2. Procédé de la revendication 1, dans lequel la réaction de la partie b et la réaction de la partie c sont conduites *in situ* et le composé IV n'est pas isolé.

3. Procédé de la revendication 1, dans lequel R₁-R₃ et R₅ sont hydrogène.


4. Procédé de la revendication 1, dans lequel R₄ est isopropyle.

5. Procédé de l'une quelconque des revendications 1 à 4 dans lequel l'agent réducteur est choisi parmi le borohydrure de sodium, le borohydrure de potassium, l'hydrure de lithium-aluminium et un complexe borane-tétrahydrofurane, de préférence NaBH₄.

6. Procédé de l'une quelconque des revendications 1 à 5, dans lequel l'agent d'halogénéation est choisi parmi le N-chlorosuccinimide (NCS), le N-bromosuccinimide (NBS), le N-iodosuccinimide (NIS), le brome et l'iode, de préférence NBS.


7. Procédé de préparation de zilpatérol ou un sel de celui-ci comprenant :

a. la réaction d'un composé de formule 3



3


avec un agent d'halogénéation pour produire un composé de formule 9




9

dans laquelle X est Cl, Br, ou I ;

b. la réaction du composé 9 avec le composé suivant



pour produire un composé de formule 10 ;



10

et

c. la réaction du composé 10 avec un agent réducteur pour produire du zilpatérol ou un sel de celui-ci.


8. Procédé de la revendication 7, dans lequel la réaction de la partie b et la réaction de la partie c sont conduites *in situ* et le composé 10 n'est pas isolé.

9. Procédé de la revendication 7, dans lequel le zilpatérol est le chlorhydrate de zilpatérol.

10. Procédé de l'une quelconque des revendications 7 à 9, dans lequel l'agent d'halogénéation est choisi parmi le N-chlorosuccinimide (NCS), le N-bromosuccinimide (NBS), le N-iodosuccinimide (NIS), le brome et l'iode.

11. Procédé de l'une quelconque des revendications 7 à 10 dans lequel l'agent réducteur est choisi parmi le borohydrure de sodium, le borohydrure de potassium, l'hydruure de lithium-aluminium et un complexe borane-tétrahydrofurane.

12. Composé de formule III ou sel de celui-ci



dans laquelle


X est Cl, Br ou I ;

R₁ est choisi parmi hydrogène, amino, alkyle, alcényle, alcynyle, aryle, benzyle, ou une version cyclique ou une version contenant un hétéroatome quelconque de ceux-ci et où chaque alkyle, alcényle, alcynyle, aryle, benzyle, et une version cyclique ou une version contenant un hétéroatome quelconque peut être substitué ou non substitué ;

R_{2a} et R_{2b} sont identiques ou différents et sont chacun indépendamment choisis parmi hydrogène, halogène, hydroxyle, amino, alkyle, alcényle, alcynyle, aryle, benzyle, alcoxy, alkylthioxy, alkylsulfonyl, alkylsulfoxy, alkylthio ou une version cyclique ou une version contenant un hétéroatome quelconque de ceux-ci et où chaque alkyle, alcényle, alcynyle, aryle, benzyle, alcoxy, alkylthioxy, alkylsulfonyl, alkylsulfoxy, alkylthio et une version cyclique ou une version contenant un hétéroatome quelconque peut être substitué ou non substitué ;


R₃ est choisi parmi hydrogène, halogène, hydroxyle, amino, alkyle, alcényle, alcynyle, aryle, benzyle, alcoxy, alkylthioxy, alkylsulfonyl, alkylsulfoxy, alkylthio ou une version cyclique ou une version contenant un hétéroatome quelconque de ceux-ci et où chaque alkyle, alcényle, alcynyle, aryle, benzyle, alcoxy, alkylthioxy, alkylsulfonyl, alkylsulfoxy, alkylthio et une version cyclique ou une version contenant un hétéroatome quelconque peut être substitué ou non substitué.

13. Composé de la revendication 12 ou sel de celui-ci, le composé étant de formule 9




dans laquelle X est Br, Cl ou I de préférence Br.

14. Composé de formule IV ou sel de celui-ci



où,
le composé est de formule 10



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 4900735 A [0001]
- US 4585770 A, Fréchet [0002] [0004] [0005] [0006] [0007] [0008] [0009] [0010] [0011] [0012] [0013]
- US 5731028 A [0013]
- US 5847124 A, Chevremont [0013]
- WO 2008119754 A [0014] [0015]
- WO 2010070004 A [0015]
- WO 2008006828 A [0016]
- WO 2008092924 A [0016]
- WO 2008044127 A [0017] [0052]

Non-patent literature cited in the description

- *J. Chem. Soc. Perkins*, 1982, 261 [0006]
- *Helv.*, 1961, vol. 44, 1278 [0009]